Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095854 | 1.00 | CCR2 (0.43) | CCR2P2RX3TBXA2RMAPTLMNA | |
| SCHEMBL12966346 | 0.88 | TBXA2R (0.42) | P2RX3TBXA2RLMNAMEN1ALDH1A1 | |
| SCHEMBL12966284 | 0.88 | P2RX3 (0.46) | CCR2P2RX3MAPTLMNAMEN1 | |
| SCHEMBL3103070 | 0.85 | ALDH1A1 (0.40) | CCR2MAPTLMNAMEN1ALDH1A1 | |
| SCHEMBL3090980 | 0.79 | LMNA (0.48) | CCR2P2RX3TBXA2RMAPTLMNA | |
| SCHEMBL9959514 | 0.78 | TP53 (0.44) | MAPTLMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3088330 | 0.78 | TP53 (0.46) | CCR2LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23630652 | 0.77 | ALOX5AP (0.49) | P2RX3TBXA2RMAPTCYP1A2CYP3A4 | |
| SCHEMBL3096637 | 0.77 | MAPT (0.52) | CCR2P2RX3MAPTLMNAMEN1 | |
| SCHEMBL38664699 | 0.75 | CCR2 (0.59) | CCR2LMNAALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933842-B1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | CCR2 2928/4885P2RX3 2324/4885TBXA2R 97/4885 |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | CCR2 2928/4885P2RX3 2324/4885TBXA2R 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.